Investor Presentation
Logotype for Brenntag SE

Brenntag (BNR) Investor Presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Brenntag SE

Investor Presentation summary

13 Aug, 2025

Strategic positioning and business model

  • Maintains global leadership in chemical distribution, operating in over 70 countries with around 600 sites and a highly diversified client and supplier base.

  • Operates two divisions: Essentials (broad industrial chemicals) and Specialties (performance chemicals), each with tailored strategies and market approaches.

  • Focuses on an asset-light, resilient business model with consistent ROCE ≥14% and a strong M&A track record, having spent €3.9bn on over 100 acquisitions since IPO.

  • Leverages digital and data-driven initiatives (DiDEX) to enhance supply chain, pricing, and customer engagement.

  • Emphasizes sustainability, aiming for net-zero GHG emissions by 2050 and leading ESG ratings in the sector.

Financial performance and capital allocation

  • Q2 2025 sales reached €3.9bn, operating gross profit €974m, and operating EBITA €246m, all declining year-over-year due to economic headwinds.

  • Free cash flow for Q2 2025 was €153m, with a working capital turnover of 7.4x, reflecting strong cash generation and disciplined capital management.

  • Maintains a dividend policy of 35–50% of profit after tax, with a strong track record of annual increases and additional share buybacks.

  • Net debt/EBITDA at 2.1x, preserving investment grade credit ratings and financial flexibility for further M&A.

  • FY 2024 operating EBITA was €1.1bn, down 12.9% from prior year, with Essentials and Specialties both experiencing margin pressure.

Transformation, growth strategy, and outlook

  • Transformation journey since 2020 has focused on divisional autonomy, digitalization, cost-out programs, and portfolio optimization.

  • Essentials division pursues a 'triple' strategy: last mile service excellence, regional/global sourcing, and targeted M&A.

  • Specialties division targets margin expansion through pricing, product mix, value-added services, and focused M&A in Life Science and Material Science.

  • Cost-out program delivered €30m savings in Q2 2025, with a target of €300m annualized by 2027.

  • 2025 outlook guides for operating EBITA of €950–1,050m, with continued macroeconomic uncertainty and a focus on efficiency, digital, and sustainability initiatives.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more